{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:39:41Z","timestamp":1790667581186,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1053\/j.semnuclmed.2022.12.005","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T04:12:57Z","timestamp":1673583177000},"page":"503-516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma"],"prefix":"10.1053","volume":"53","author":[{"given":"Xue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-6470","authenticated-orcid":false,"given":"Hiroshi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1073-0878","authenticated-orcid":false,"given":"Tomo","family":"Hiromasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kayano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Kinuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0001","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0002","doi-asserted-by":"crossref","first-page":"e2251","DOI":"10.1210\/clinem\/dgaa965","article-title":"Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: a population-based study","volume":"106","author":"Ebbehoj","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0003","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0004","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","article-title":"Laboratory evaluation of pheochromocytoma and paraganglioma","volume":"60","author":"Eisenhofer","year":"2014","journal-title":"Clin Chem"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0005","article-title":"Advances in Adrenal and Extra-adrenal Paraganglioma: Practical Synopsis for Pathologists","author":"Juhlin","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0006","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0007","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.bjc.6601276","article-title":"Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters","volume":"89","author":"K\u00f6lby","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0008","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ijc.2910470615","article-title":"Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging","volume":"47","author":"Gaze","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0009","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Ta\u00efeb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0010","first-page":"1613","article-title":"Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma","volume":"49","author":"Ilias","year":"2008","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0011","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1210\/jc.2009-1248","article-title":"Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma","volume":"94","author":"Timmers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0012","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1210\/jc.2009-2352","volume":"95","author":"Fottner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0013","first-page":"1448","article-title":"Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial","volume":"50","author":"Wiseman","year":"2009","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2265.2008.03256.x","article-title":"123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation","volume":"69","author":"Bhatia","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0015","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2018-02355","article-title":"Impact of 123 I-MIBG scintigraphy on clinical decision making in pheochromocytoma and paraganglioma","author":"Rao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00006231-200607000-00006","article-title":"Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study","volume":"27","author":"Lumachi","year":"2006","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0017","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0018","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1200\/JCO.2006.09.6297","article-title":"Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma","volume":"25","author":"Timmers","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0019","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00259-011-1962-2","article-title":"Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification","volume":"39","author":"Kroiss","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-012-2119-7","article-title":"A comparison of the performance of 68Ga-DOTATATE PET\/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma","volume":"39","author":"Maurice","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00259-014-2892-6","article-title":"(68)Ga-DOTATOC PET\/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT\/CT","volume":"42","author":"Kroiss","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0022","first-page":"1232","article-title":"111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas","volume":"49","author":"Koopmans","year":"2008","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0023","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12149-017-1162-7","article-title":"Compared to 123I-MIBG SPECT\/CT, 18F-DOPA PET\/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma","volume":"31","author":"Kroiss","year":"2017","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0024","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nucmedbio.2019.04.003","article-title":"68Ga-DOTATOC PET\/CT in the localization of head and neck paraganglioma compared with 18F-DOPA PET\/CT and 123I-MIBG SPECT\/CT","volume":"71","author":"Kroiss","year":"2019","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0025","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1210\/jc.2011-0333","article-title":"Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy","volume":"96","author":"King","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0026","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000381458","article-title":"usefulness of somatostatin receptor scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-metaiodobenzylguanidine scintigraphy in patients with SDHx gene-related pheochromocytomas and paragangliomas detected by computed tomography","volume":"101","author":"Micha\u0142owska","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0027","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/MNM.0b013e328345a340","article-title":"Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma","volume":"32","author":"Rufini","year":"2011","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0028","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0029","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0030","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1038\/s41598-019-43880-6","article-title":"A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma","volume":"9","author":"Wakabayashi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0031","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12149-021-01699-0","article-title":"An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma","volume":"36","author":"Inaki","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0032","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"van Hulsteijn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0033","doi-asserted-by":"crossref","first-page":"dgz074","DOI":"10.1210\/clinem\/dgz074","article-title":"Long-term outcomes of 125 patients with metastatic pheochromocytoma or paraganglioma treated with 131-I MIBG","volume":"105","author":"Thorpe","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0034","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12149-021-01685-6","article-title":"Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy","volume":"36","author":"Hiromasa","year":"2022","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0035","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0036","doi-asserted-by":"crossref","first-page":"E1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0037","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2017-02030","article-title":"Phase 1 study of high-specific-activity I-131 MIBG for metastatic and\/or recurrent pheochromocytoma or paraganglioma","volume":"103","author":"Noto","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0038","first-page":"623","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0039","first-page":"288","article-title":"[131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma","volume":"35","author":"Lumbroso","year":"1991","journal-title":"J Nucl Biol Med Turin Italy 1991"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0040","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1507\/endocrj.EJ14-0211","article-title":"Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry","volume":"61","author":"Yoshinaga","year":"2014","journal-title":"Endocr J"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0041","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","article-title":"High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma","volume":"98","author":"Rose","year":"2003","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0042","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/bjc.2013.365","article-title":"Sequelae and survivorship in patients treated with (131)I-MIBG therapy","volume":"109","author":"Sze","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0043","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/qjmed\/hcu208","article-title":"Management of metastatic phaeochromocytoma and paraganglioma: use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre","volume":"108","author":"Rutherford","year":"2015","journal-title":"QJM Mon J Assoc Physicians"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0044","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma: single center experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0045","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med Turin Italy 1991"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0046","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0047","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0048","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1196\/annals.1353.050","article-title":"Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG)","volume":"1073","author":"Fitzgerald","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0049","first-page":"100","article-title":"(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0050","first-page":"361","article-title":"Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands","volume":"13","author":"Hartley","year":"2001","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0051","first-page":"1082","article-title":"In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas","volume":"74","author":"Reubi","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0052","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0053","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00259-002-0939-6","article-title":"Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas","volume":"29","author":"Schmidt","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0054","first-page":"685","article-title":"[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas","volume":"86","author":"van der Harst","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jcem.86.2.7194","article-title":"Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors","volume":"86","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0056","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s002590100639","article-title":"Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data","volume":"28","author":"Hofmann","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0057","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0058","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","article-title":"DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals","volume":"30","author":"Wild","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0059","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0042-1751030","article-title":"Comparison of the sensitivity of 68 Ga-DOTATATE PET\/CT with other imaging modalities in detecting head and neck paraganglioma: experience from western india","volume":"21","author":"Dodamani","year":"2022","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0060","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4103\/ijem.ijem_307_21","article-title":"The utility of 68Ga-DOTATATE PET\/CT in localizing primary\/metastatic pheochromocytoma and paraganglioma: asian indian experience","volume":"25","author":"Jaiswal","year":"2021","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0061","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.3390\/cancers14163886","article-title":"Performances of functional and anatomic imaging modalities in succinate dehydrogenase a-related metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Patel","year":"2022","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0062","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","article-title":"Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases","volume":"43","author":"Archier","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0063","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1007\/s00259-016-3357-x","article-title":"PET\/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT\/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma","volume":"43","author":"Janssen","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0064","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1007\/s00259-013-2548-y","article-title":"A retrospective comparison between 68Ga-DOTA-TOC PET\/CT and 18F-DOPA PET\/CT in patients with extra-adrenal paraganglioma","volume":"40","author":"Kroiss","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0065","first-page":"841","article-title":"68Ga-DOTANOC PET\/CT for baseline evaluation of patients with head and neck paraganglioma","volume":"54","author":"Sharma","year":"2013","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0066","first-page":"1864","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0067","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00259-013-2598-1","article-title":"Diagnostic accuracy of (68)Ga-DOTANOC PET\/CT imaging in pheochromocytoma","volume":"41","author":"Sharma","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0068","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic Performance of (68)Ga-DOTATATE PET\/CT, (18)F-FDG PET\/CT and (131)I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0069","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to Other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00330-011-2289-x","article-title":"Prospective evaluation of 68Ga-DOTA-NOC PET-CT in phaeochromocytoma and paraganglioma: preliminary results from a single centre study","volume":"22","author":"Naswa","year":"2012","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0071","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0072","first-page":"1236","article-title":"Functional imaging signature of patients presenting with polycythemia\/paraganglioma syndromes","volume":"58","author":"Janssen","year":"2017","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0073","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, nccn clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0074","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"Bodei","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0075","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0076","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177lu-dotatate in the phase iii netter-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0077","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2174\/1568026611212230006","article-title":"Beta-emitting radionuclides for peptide receptor radionuclide therapy","volume":"12","author":"Parus","year":"2012","journal-title":"Curr Top Med Chem"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0078","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0079","first-page":"334","article-title":"Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma","volume":"52","author":"Forrer","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0080","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0081","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-0032-1311637","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL)","volume":"44","author":"Zovato","year":"2012","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0082","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s00259-015-3029-2","article-title":"Peptide receptor radionuclide therapy with (90)Y\/(177)Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)","volume":"42","author":"Puranik","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0083","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/jso.24553","article-title":"Peptide receptor radionuclide treatment and (131)i-mibg in the management of patients with metastatic\/progressive phaeochromocytomas and paragangliomas","volume":"115","author":"Nastos","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0084","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-016-0737-9","article-title":"Peptide receptor radionuclide therapy for metastatic paragangliomas","volume":"33","author":"Pinato","year":"2016","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/RLU.0000000000001629","article-title":"Peptide receptor radionuclide therapy with 177lu-octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years\u2019 assessment","volume":"42","author":"Hamiditabar","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0086","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0087","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MNM.0000000000000874","article-title":"177lu-dotatate therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update","volume":"39","author":"Demirci","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0088","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177lu-dota-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0089","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1530\/EJE-18-0901","article-title":"Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177lu-dotatate","volume":"181","author":"Zandee","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0090","doi-asserted-by":"crossref","first-page":"E909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0091","doi-asserted-by":"crossref","first-page":"E952","DOI":"10.3390\/jcm8070952","article-title":"A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation","volume":"8","author":"Kolasinska-\u0106wik\u0142a","year":"2019","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0092","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1530\/EC-20-0292","article-title":"177lu-dotatate therapy in metastatic\/inoperable pheochromocytoma-paraganglioma","volume":"9","author":"Jaiswal","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0093","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/j.wneu.2020.07.165","article-title":"Somatostatin receptor-targeted radioligand therapy in head and neck paraganglioma","volume":"143","author":"Roll","year":"2020","journal-title":"World Neurosurg"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0094","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.esmoop.2021.100171","article-title":"Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials","volume":"6","author":"Severi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12149-020-01541-z","article-title":"131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy","volume":"35","author":"Parghane","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0096","doi-asserted-by":"crossref","first-page":"778322","DOI":"10.3389\/fendo.2022.778322","article-title":"[177Lu]Lu-DOTA-TATE and [131I]MIBG phenotypic imaging-based therapy in metastatic\/inoperable pheochromocytomas and paragangliomas: comparative results in a single center","volume":"13","author":"Prado-Wohlwend","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0097","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0098","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/wjnm.WJNM_16_17","article-title":"Correlation between standardized uptake value of 68Ga-DOTA-NOC positron emission tomography\/computed tomography and pathological classification of neuroendocrine tumors","volume":"17","author":"Kaewput","year":"2018","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0099","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.292.8.943","article-title":"Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations","volume":"292","author":"Neumann","year":"2004","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0100","doi-asserted-by":"crossref","first-page":"T91","DOI":"10.1530\/ERC-15-0268","article-title":"15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1-5","volume":"22","author":"Benn","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0101","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.humpath.2014.11.012","article-title":"Increased SSTR2A and SSTR3 expression in succinate dehydrogenase-deficient pheochromocytomas and paragangliomas","volume":"46","author":"Elston","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0102","doi-asserted-by":"crossref","first-page":"625312","DOI":"10.3389\/fendo.2021.625312","article-title":"Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: old players in a new precision medicine world","volume":"12","author":"Patel","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0103","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/RLU.0000000000000935","article-title":"Peptide receptor radionuclide therapy-induced hepatotoxicity in patients with metastatic neuroendocrine tumors","volume":"40","author":"Riff","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0104","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0105","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate","volume":"35","author":"de Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11912-017-0567-8","article-title":"Radionuclide therapy for neuroendocrine tumors","volume":"19","author":"Cives","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0107","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00259-013-2559-8","article-title":"Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours","volume":"41","author":"Romer","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0108","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0109","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00000421-199908000-00008","article-title":"Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy","volume":"22","author":"Sisson","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0110","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-0032-1308992","article-title":"External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG","volume":"44","author":"Fishbein","year":"2012","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0111","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumors: a long-term-outcome, toxicity, survival, and quality-of-life study","volume":"42","author":"Ballal","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0112","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-019-0484-y","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas","volume":"9","author":"Yadav","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0113","first-page":"147","article-title":"biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET\/CT imaging study of patients with neuroendocrine malignancies","volume":"59","author":"Pandit-Taskar","year":"2018","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0114","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00259-020-04830-x","article-title":"Improved resolution and sensitivity of [18F]MFBG PET compared with [123I]MIBG SPECT in a patient with a norepinephrine transporter-expressing tumour","volume":"48","author":"Pauwels","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/RLU.0000000000003997","article-title":"Similar findings on 18F-MFBG PET\/CT and 68Ga-DOTATATE PET\/CT in a patient with widespread metastatic pheochromocytoma","volume":"47","author":"Wang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0116","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000003997","article-title":"18F-MFBG PET\/CT is an effective alternative of 68Ga-DOTATATE PET\/CT in the evaluation of metastatic pheochromocytoma and paraganglioma","author":"Wang","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0117","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1158\/1078-0432.CCR-12-0298","article-title":"Molecular pathways: targeted \u03b1-particle radiation therapy","volume":"19","author":"Baidoo","year":"2013","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0118","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000494760","article-title":"Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy","volume":"108","author":"Navalkissoor","year":"2019","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0119","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/bc00018a006","article-title":"1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation","volume":"3","author":"Vaidyanathan","year":"1992","journal-title":"Bioconjug Chem"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0121","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.tranon.2019.04.008","article-title":"Preclinical evaluation of the acute radiotoxicity of the \u03b1-emitting molecular-targeted therapeutic agent 211At-MABG for the treatment of malignant pheochromocytoma in normal mice","volume":"12","author":"Sudo","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0122","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0123","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1007\/s00259-022-05826-5","article-title":"225Ac-DOTATATE therapy in a case of metastatic pheochromocytoma","volume":"49","author":"Peng","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.12.005_bib0124","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:41:19Z","timestamp":1757544079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0001299822001179"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.12.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}